Is BioLineRx Stock a Good Investment?
BioLineRx Investment Advice | BLRX |
- Examine BioLineRx's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research BioLineRx's leadership team and their track record. Good management can help BioLineRx navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact BioLineRx's business and its evolving consumer preferences.
- Compare BioLineRx's performance and market position to its competitors. Analyze how BioLineRx is positioned in terms of product offerings, innovation, and market share.
- Check if BioLineRx pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about BioLineRx's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in BioLineRx stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if BioLineRx is a good investment.
Sell | Buy |
Strong Sell
Market Performance | OK | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine BioLineRx Stock
Researching BioLineRx's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 0.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLineRx has Price/Earnings To Growth (PEG) ratio of 0.2. The entity recorded a loss per share of 6.0. The firm last dividend was issued on the 15th of July 2019. BioLineRx had 1:40 split on the 30th of January 2025.
To determine if BioLineRx is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding BioLineRx's research are outlined below:
| BioLineRx is way too risky over 90 days horizon | |
| BioLineRx appears to be risky and price may revert if volatility continues | |
| BioLineRx has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 28.94 M. Net Loss for the year was (9.22 M) with profit before overhead, payroll, taxes, and interest of 14.5 M. | |
| BioLineRx currently holds about 43.15 M in cash with (43.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| Latest headline from finance.yahoo.com: H.C. Wainwright Reaffirms Buy on BioLineRx Ltd. After ASCO 2025 |
BioLineRx Quarterly Cash And Short Term Investments |
|
BioLineRx uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in BioLineRx. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to BioLineRx's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 22nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact BioLineRx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises BioLineRx's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-25 | 2023-03-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2024-11-04 | 2024-09-30 | -0.1 | -0.0728 | 0.0272 | 27 | ||
2022-09-30 | 2022-06-30 | -0.11 | -0.15 | -0.04 | 36 | ||
2022-03-16 | 2021-12-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2020-11-23 | 2020-09-30 | -0.35 | -0.3 | 0.05 | 14 | ||
2019-11-19 | 2019-09-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2022-05-25 | 2022-03-31 | -0.09 | -0.15 | -0.06 | 66 | ||
2024-08-15 | 2024-06-30 | -0.14 | 0.0061 | 0.1461 | 104 |
BioLineRx Target Price Consensus
BioLineRx target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. BioLineRx's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most BioLineRx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand BioLineRx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of BioLineRx, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBioLineRx Target Price Projection
BioLineRx's current and average target prices are 4.60 and 26.00, respectively. The current price of BioLineRx is the price at which BioLineRx is currently trading. On the other hand, BioLineRx's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On BioLineRx Target Price
BioLineRx Analyst Ratings
BioLineRx's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about BioLineRx stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of BioLineRx's financials, market performance, and future outlook by experienced professionals. BioLineRx's historical ratings below, therefore, can serve as a valuable tool for investors.Know BioLineRx's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as BioLineRx is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BioLineRx backward and forwards among themselves. BioLineRx's institutional investor refers to the entity that pools money to purchase BioLineRx's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Captrust Financial Advisors | 2025-03-31 | 0.0 | Creative Planning Inc | 2024-12-31 | 0.0 | Envestnet Asset Management Inc | 2024-12-31 | 0.0 | Susquehanna International Group, Llp | 2024-12-31 | 0.0 | Cutter & Co Brokerage, Inc. | 2024-12-31 | 0.0 | Atria Wealth Solutions, Inc. | 2024-12-31 | 0.0 | Rathbone Brothers Plc | 2024-12-31 | 0.0 | Watts Gwilliam And Company, Llc | 2025-03-31 | 0.0 | Wealth Enhancement Advisory Services, Llc | 2024-12-31 | 0.0 | Wells Fargo & Co | 2025-03-31 | 3 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 2.2 K |
BioLineRx's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.71 M.Market Cap |
|
BioLineRx's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (0.87) | (0.91) | |
| Return On Assets | (0.24) | (0.25) | |
| Return On Equity | (0.69) | (0.72) |
Determining BioLineRx's profitability involves analyzing its financial statements and using various financial metrics to determine if BioLineRx is a good buy. For example, gross profit margin measures BioLineRx's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of BioLineRx's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in BioLineRx's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioLineRx. Check BioLineRx's Beneish M Score to see the likelihood of BioLineRx's management manipulating its earnings.
Evaluate BioLineRx's management efficiency
BioLineRx has return on total asset (ROA) of (0.2198) % which means that it has lost $0.2198 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2003) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.34 in 2025. Return On Capital Employed is likely to drop to -0.91 in 2025. At this time, BioLineRx's Total Assets are fairly stable compared to the past year. Intangible Assets is likely to rise to about 10.5 M in 2025, whereas Other Assets are likely to drop 0.86 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.01 | 0.01 | |
| Enterprise Value Over EBITDA | 6.63 | 6.96 | |
| Price Book Value Ratio | 1.59 | 1.81 | |
| Enterprise Value Multiple | 6.63 | 6.96 | |
| Price Fair Value | 1.59 | 1.81 | |
| Enterprise Value | 26 M | 41.9 M |
The strategic initiatives led by BioLineRx's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Beta 0.948 |
Basic technical analysis of BioLineRx Stock
As of the 23rd of July, BioLineRx shows the Mean Deviation of 4.36, risk adjusted performance of 0.1212, and Downside Deviation of 5.99. BioLineRx technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioLineRx's Outstanding Corporate Bonds
BioLineRx issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioLineRx uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioLineRx bonds can be classified according to their maturity, which is the date when BioLineRx has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand BioLineRx's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing BioLineRx's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1212 | |||
| Market Risk Adjusted Performance | (1.11) | |||
| Mean Deviation | 4.36 | |||
| Semi Deviation | 4.8 | |||
| Downside Deviation | 5.99 | |||
| Coefficient Of Variation | 802.69 | |||
| Standard Deviation | 7.26 | |||
| Variance | 52.67 | |||
| Information Ratio | 0.1 | |||
| Jensen Alpha | 1.03 | |||
| Total Risk Alpha | (0.46) | |||
| Sortino Ratio | 0.1212 | |||
| Treynor Ratio | (1.12) | |||
| Maximum Drawdown | 60.43 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 11.31 | |||
| Downside Variance | 35.87 | |||
| Semi Variance | 23.02 | |||
| Expected Short fall | (5.48) | |||
| Skewness | 1.87 | |||
| Kurtosis | 11.45 |
| Risk Adjusted Performance | 0.1212 | |||
| Market Risk Adjusted Performance | (1.11) | |||
| Mean Deviation | 4.36 | |||
| Semi Deviation | 4.8 | |||
| Downside Deviation | 5.99 | |||
| Coefficient Of Variation | 802.69 | |||
| Standard Deviation | 7.26 | |||
| Variance | 52.67 | |||
| Information Ratio | 0.1 | |||
| Jensen Alpha | 1.03 | |||
| Total Risk Alpha | (0.46) | |||
| Sortino Ratio | 0.1212 | |||
| Treynor Ratio | (1.12) | |||
| Maximum Drawdown | 60.43 | |||
| Value At Risk | (6.53) | |||
| Potential Upside | 11.31 | |||
| Downside Variance | 35.87 | |||
| Semi Variance | 23.02 | |||
| Expected Short fall | (5.48) | |||
| Skewness | 1.87 | |||
| Kurtosis | 11.45 |
Consider BioLineRx's intraday indicators
BioLineRx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLineRx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioLineRx time-series forecasting models is one of many BioLineRx's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLineRx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
BioLineRx Stock media impact
There is far too much social signal, news, headlines, and media speculation about BioLineRx that are available to investors today. This information is accessible both publicly - through BioLineRx's media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of BioLineRx-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of BioLineRx news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of BioLineRx relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to BioLineRx's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive BioLineRx alpha.
BioLineRx Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards BioLineRx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioLineRx Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Raziel Fried | Treasurer Director | Profile | |
| Adam Esq | General Compliance | Profile | |
| Jael MSc | QA RA | Profile | |
| CPA MBA | Chief Officer | Profile |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.